{"id":52768,"date":"2024-11-13T10:10:20","date_gmt":"2024-11-13T10:10:20","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=52768"},"modified":"2024-11-13T10:10:20","modified_gmt":"2024-11-13T10:10:20","slug":"defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-welcomes-dr-svetlana-selivanova-to-board-of-directors\/52768\/","title":{"rendered":"Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors"},"content":{"rendered":"
Dr Selivanova brings over 20 years of expertise in radiopharmaceutical development, spanning from early-stage research to clinical trials. She holds a Master of Science in chemistry and a PhD in radiopharmaceutical chemistry and radiobiology.<\/p>\n
Dr Selivanova is currently the Section Head for Radiochemistry and Medical Applications at Canadian Nuclear Laboratories (CNL) and serves as an adjunct professor at the Faculty of Pharmacy, Universit\u00e9 Laval.<\/p>\n
Before her role at CNL, she held senior research and management positions at CHU de Quebec-Universit\u00e9 Laval, Sherbrooke University Hospital, and the Center for Radiopharmaceutical Sciences at ETH Zurich in Switzerland.<\/p>\n
An active contributor to her field, Dr Selivanova serves as an Executive Member of the Canadian Association of Radiopharmaceutical Scientists, President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Radiopharmaceutical Sciences Council, and a member of the SNMMI Committee on Radiopharmaceuticals.<\/p>\n
Internationally, she provides expert consultation to the International Atomic Energy Agency (IAEA) and the European Research Council. Her research interests include the development and clinical translation of novel radiopharmaceuticals, as well as nuclear imaging to explore biochemical pathways in vivo.<\/p>\n
Among Dr Selivanova\u2019s significant contributions is her role in the development of technetium-99m production using cyclotron technology, as well as her work on investigational radiopharmaceuticals for prostate cancer targeting the prostate-specific membrane antigen.<\/p>\n
\u201cWe are proud to have Dr Svetlana Selivanova joining our board of directors,\u201d commented S\u00e9bastien Plouffe, President, CEO, and Founder of Defence Therapeutics.<\/p>\n
\u201cShe is a very strong addition to our company. Defence\u2019s strategy is to develop radio-immuno-conjugates using our Accum\u00ae<\/sup> platform<\/a>. Dr Selivanova has extensive knowledge and experience in this field and will strengthen and accelerate our radiopharmaceuticals programmes<\/a>.\u201d<\/p>\n Dr Selivanova expressed her excitement in joining Defence Therapeutics, stating: \u201cI am honoured to join Defence Therapeutics board of directors. I believe that Defence\u2019s Accum\u00ae<\/sup> technology platform has great potential for the development of targeted radiopharmaceutical therapies.\u201d<\/p>\n In alignment with Defence\u2019s stock option plan, the company has granted Dr Selivanova 100,000 incentive stock options. Each option vests immediately and is exercisable at 60 cents per share, with a three-year term from the grant date.<\/p>\n Defence Therapeutics also announced that Dr Raimar Lobenberg will be stepping down from the board. The company extends its gratitude to Dr Lobenberg for his valuable contributions to the board.<\/p>\n","protected":false},"excerpt":{"rendered":" Defence Therapeutics has announced that Dr Svetlana Selivanova has joined its board of directors, effective immediately.<\/p>\n","protected":false},"author":15,"featured_media":52770,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[23535],"tags":[24628],"acf":[],"yoast_head":"\nDr Selivanova\u2019s enthusiasm for Defence Therapeutics\u2019 future<\/h3>\n